Table 1 Completed CD30-Directed CAR-T Cell Clinical Trials for Patients with Relapsed/Refractory CD30+ Lymphoma
From: Challenges of driving CD30-directed CAR-T cells to the clinic
Trial | Wang et al. | Ramos et al. |
|---|---|---|
Costimulatory Domain | 4-1BB | CD28 |
Viral Vector | Lentivirus | Gammaretrovirus |
Conditioning Chemotherapy | FC, GMC, PC | None |
Doses | 1.1–2.1 × 107 CAR-T cells/kg | 2 × 107, 1 × 108, 2 × 108 CAR-T/m2 |
Number of Patients Treated | 18 patients (17 HL, 1 cutaneous ALCL) | 9 patients (6 HL, 1 cutaneous ALCL, 1 systemic ALCL, 1 DLBCL evolved to HL) |
Responses | ORR 39% (7 PR); 6 with SD | ORR 33% (2 CR, 1 continued CR); 3 with SD |